Renal Cancer

Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Renal Cancer Information Center has current, evidence-based information for you. Get the facts about renal cancer early detection, treatment, and survivorship, and stay up to date with ongoing renal cancer research that could impact your treatment decisions through our daily cancer news.

CancerConnect Renal Cancer Community & Discussions

You are not alone—The CancerConnect Renal Cancer Community is the leading Social Media Application for Renal Cancer patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.

RENAL CANCER NEWS TIPS & FEATURES

New Drug Beats Standard Therapy in Advanced Kidney Cancer

December 13th, 2016

New Drug Beats Standard Therapy in Advanced Kidney Cancer

An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, […]


Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer

December 5th, 2016

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. […]


Obesity Linked to Improved Survival in Kidney Cancer

September 12th, 2016

Obesity Linked to Improved Survival in Kidney Cancer

Obesity almost always increases cancer risk and worsens outcomes, but researchers led by scientists at Dana-Farber Cancer Institute report that overweight patients with advanced kidney […]


Surgery Can Lengthen Survival of Metastatic Kidney Cancer Patients Treated with Targeted Therapies, Study Finds

July 6th, 2016

Surgery Can Lengthen Survival of Metastatic Kidney Cancer Patients Treated with Targeted Therapies, Study Finds

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only about three in 10 […]


Lenvima® Approved for Kidney Cancer

May 24th, 2016

Lenvima® Approved for Kidney Cancer

The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced […]


Cabometyx™ Approved for Kidney Cancer

May 10th, 2016

Cabometyx™ Approved for Kidney Cancer

The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx™ (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The […]


Worth a Look: It’s Kidney Cancer Awareness Month

March 18th, 2016

Worth a Look: It’s Kidney Cancer Awareness Month

The kidneys are two (or one) bean-shaped organs about the size of a fist and are located near the middle of your back on either […]


Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide

March 15th, 2016

Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide

If you are battling kidney cancer, otherwise known as renal cell carcinoma (RCC), The DART Study may be the next treatment option for you to consider. Dalantercept, in combination with […]


FDA Approves Opdivo for Renal Cell Carcinoma

November 25th, 2015

FDA Approves Opdivo for Renal Cell Carcinoma

The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma […]


COMETRIQ® Improves Progression-Free Survival in Kidney Cancer

October 15th, 2015

COMETRIQ® Improves Progression-Free Survival in Kidney Cancer

According to a recently published study in the New England Journal of Medicine, the targeted agent, COMETRIQ® (cabozantinib), significantly improves the time to cancer progression […]


More News →